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Objective: We aimed to investigate the prevalence of the metabolic syndrome (MetS) and its individual
components in subjects with bipolar disorder (BD) compared to those with major depressive disorder (MDD)
and non-psychiatric controls.
Methods:Weexamined 2431 participants (mean age 44.3± 13.0, 66.1% female), of whom 241 had BD; 1648 had
MDD; and 542 were non-psychiatric controls. The MetS was ascertained according to NCEP ATP III criteria.
Multivariable analyses were adjusted for age, sex, ethnicity, level of education, smoking status and severity of
depressive symptoms, and in the case of BD subjects, also for psychotropic medication use.
Results: Subjects with BD had a signiﬁcantly higher prevalence of MetS when compared to subjects with MDD
and non-psychiatric controls (28.4% vs. 20.2% and 16.5%, respectively, p b 0.001), also when adjusted for
sociodemographic and lifestyle factors (OR 1.52, 95% CI: 1.09–2.12, p= 0.02 compared to MDD; OR 1.79, 95%
CI: 1.20–2.67, p = 0.005 compared to non-psychiatric controls). The differences between BD subjects with
controls could partly be ascribed to a higher mean waist circumference (91.0 cm vs. 88.8, respectively, p= 0.03).
In stratiﬁed analysis, the differences in the prevalence of MetS between patients with BD and MDD were found in
symptomatic but not in asymptomatic cases.
Conclusion: This study conﬁrms a higher prevalence of MetS in patients with BD compared to both MDD patients
and controls. Speciﬁcally at risk are patients with a higher depression score and abdominal obesity.© 2015 Elsevier Inc. All rights reserved.Introduction
Bipolar disorder (BD) is one of the world's 25 most disabling condi-
tions with a prevalence of approximately 1–5% in the general popula-
tion [1,2]. BD is a chronic illness associated with substantial morbidity,
disability, and mortality with the most prevalent medical illnesses
being cardiovascular disease, diabetes mellitus, obesity and thyroid
disease [3]. The high prevalence of these medical conditions may be
due to an increased prevalence of metabolic risk factors in patients
with BD, such as abdominal obesity, increased triglycerides, decreased: PsyQ, The Hague, Department
etherlands
isorders,Max Euwelaan 60–80,
60; fax: +31 883584210.
va).high-density lipoprotein (HDL), and hypertension [4]. Findings from a
previous review [5] and meta-analysis [6] indicated that patients with
BD are at high risk for metabolic syndrome (MetS).
The MetS represents a cluster of cardiovascular and metabolic abnor-
malities including abdominal obesity, hypertension, dyslipidemia and in-
sulin resistance [7]. Screening for MetS may be of importance to help
decrease the risk of cardiovascular disease and diabetes mellitus type 2
in individuals with BD [3]. Recent reviews concluded that MetS is highly
prevalent among patients with BD, with prevalence ranging from
17–53% and a prevalence proportion ratio of 1.6 when compared with
the general population [5,8]. Additionally, co-occurringMetS in BD popu-
lation is associated with a more severe clinical presentation of BD,
suicidality, and decreased functional recovery [9–11]. Several mecha-
nisms have been hypothesized to explain the association between MetS
and BD. These include side effects of psychotropic medications, adoption
of unhealthy lifestyles, neuroendocrine and immuno-inﬂammatory
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studies reporting on the prevalence of MetS in BD used either non-
psychiatric controls [12,13] or subjectswith schizophrenia as comparison
groups [14–16] and the burden of evidence varies considerably by
geographic area [5].
Therefore, our ﬁrst aim was to investigate the prevalence of MetS in
subjects with BD compared to those with major depressive disorder
(MDD) and a non-psychiatric control group in the Netherlands. Second,
this study aimed to elucidate which of the individual MetS components
were most strongly associated with BD. Third, more detailed analyses
were performed to explorewhether sociodemographic factors, smoking
status, and psychotropic medication [17,18] contributed to individual
MetS components in BD.
Methods
Sample and procedure
Subjects selected for these analyses participated in the 2-year
follow-up (data collection from September 2006 to February 2009) as-
sessment of the Netherlands Study of Depression and Anxiety
(NESDA); and in the 2-year follow-up (data collection from December
2009 to January 2011) assessment of the Bipolar Stress Study. NESDA
is an ongoing longitudinal cohort study including 2981 persons aged
18 to 65 years, designed to examine the long-term course and conse-
quences of depressive and anxiety disorders. Subjects in the NESDA
study were selected to represent of range of depressive and anxiety
symptoms and included subjects without a history of depressive or
anxiety disorders (‘non-psychiatric controls’). Subjects with a primary
psychiatric diagnosis other than depression and anxiety (e.g. psychotic
disorder, obsessive compulsive disorder, or severe addiction disorder)
were not invited to participate in NESDA. All subjects (N = 2596,
87.1%) in the 2-year follow-up assessment were recruited from the
community or from primary or specialized mental health care settings
in 3 Dutch regions (i.e., Amsterdam, Groningen, Leiden). The 2-year
follow-up assessment consisted of a face-to-face interview, written
questionnaires, and biological measurements. For the purpose of this
study, the data from the 2-year follow-up were selected as this was
the time point at which BD was ﬁrst diagnosed in the NESDA study.
The study design is described elsewhere in more detail [19,20].
The study protocol was approved by the Ethical Review Board of each
participating center, and all patients signed informed consent.
The Bipolar Stress Study is a 2-year longitudinal cohort study,
designed to identify risk factors that have an impact on the clinical
course and the treatment of outpatients with BD. Subjects in the Bipolar
Stress Study were outpatients with BD type 1, BD type 2, and BD Not
Otherwise Speciﬁed (NOS). All 122 subjects were recruited from the
outpatient Clinic for Mood Disorders in The Hague, The Netherlands.
The 2-year follow-up assessment consisted of a face-to-face interview,
written questionnaires, and biological measures. For the purpose of
this study, the data from the 2-year follow-up were selected as this
was the time point at which MetS components were measured in the
Bipolar Stress Study. The study design is described elsewhere inmore de-
tail [21]. The study was approved by the local Medical Ethics Committee,
and all patients signed informed consent.
In the 2-year follow-up assessment of the NESDA study, data were
collected among 2596 subjects (response rate was 87.1%) [19] diag-
nosed with anxiety disorder, depressive disorders, BD, or no history of
a psychiatric disorder (control). We excluded 276 subjects diagnosed
only with a lifetime anxiety disorder and 5 subjects diagnosed only
with lifetime dysthymia. This resulted in a sample of 2315 (89.2%)
subjects. This sample was enriched with 122 BD patients from the
Bipolar Stress Study. From the latter group, 6 patients were excluded
aged N65 years (as the age range within the NESDA study was
18–65 years). Thus 2431 subjects (BD = 241; MDD = 1648;
controls = 542) were included in the analyses (Fig. 1).In the present study, there were missing data for some variables as
follows: MetS 9.9%; waist circumference 5.6%; triglyceride level 12.5%;
HDL-cholesterol 12.3%; systolic and diastolic blood pressure 5.6%; and
glucose level 11.7%.
BD subjects from the NESDA study did not differ from BD subjects in
the Bipolar Stress Study in gender (p = 0.41), ethnicity (p = 0.93),
smoking status (p = 0.51), and use of tricyclic antidepressants (TCA,
p= 0.70) or other antidepressants (p= 0.92), but they were younger
(p = 0.01), used more often selective serotonin re-uptake inhibitors
(SSRI, p=0.01), used less antipsychotic, antiepileptic and lithiummed-
ication (all p b 0.001), andhad a higher severity of depressive symptoms
(p b 0.001).
Measures
Bipolar and major depressive disorder
In the NESDA study, MDD or BD were diagnosed according to
the fourth edition of the Diagnostic and Statistical Manual for Mental
Disorders (DSM-IV) criteria using the Composite International Diagnostic
Interview [22].
In the Bipolar Stress Study, BDwas diagnosed according to the DSM-
IV Text Revision (DSM-IV-TR) criteria using the Dutch version of the
MINI International Neuropsychiatric Interview Plus (version 5.00-R;
MINI-PLUS) [23].
The metabolic syndrome
MetS was deﬁned according to the National Cholesterol Education
Program—Adult Treatment Panel III [24] deﬁnition. It requires the
presence of three or more of the following ﬁve criteria: 1) abdominal
obesity, i.e., waist circumference ≥102 cm in men and ≥88 cm in
women; 2) hypertriglyceridemia, i.e., elevated triglyceride level
≥1.70 mmol/L; 3) low high-density lipoprotein (HDL) cholesterol, i.e.
HDLb1.03mmol/L inmenandb1.30mmol/L inwomen;4)hypertension,
i.e., elevated blood pressure ≥130/85 mmHg or use of antihypertensive
medication, indicating that those patients using antihypertensive med-
ication, irrespective of their blood pressure, were still considered as
fulﬁlling this criterion for hypertension; and 5) hyperglycemia,
i.e., elevated fasting glucose level≥6.1mmol/L or anti-diabetic medica-
tion. Additionally, in line with previous research [25], the number of
MetS components was used as an indicator of severity of metabolic
abnormalities. Furthermore, in addition to the MetS, associations with
individual metabolic components as continuous variables were exam-
ined to investigate consistency across components. In line with previ-
ous research [26], in the analyses of individual continuous metabolic
components, if the participant had a glucose level of b7 mmol/L
[126mg/dL] and used antidiabetic medication, the participant's glucose
levelwas coded as 7mmol/L [126mg/dL]. If the participant used antihy-
pertensivemedication, an additional 10mmHgwas added to the systol-
ic blood pressure and an additional 5 mmHg to the diastolic blood
pressure [27]. Waist circumference was measured with a measuring
tape to the nearest 0.1 cm midway between the lower rib margin
and the iliac crest, upon light clothing. In the NESDA study, levels of
HDL-cholesterol and triglycerides were determined using enzymatic
colorimetric assay; the levels of glucosewere determined using hexoki-
nase method. The lipids were sampled using a heparine tube whereas
the glucose were sampled using a sodium ﬂuoride tube and kept on
ice. In the Bipolar Stress Study, a Modular P800, E170 analyzer and cor-
responding reagents (Roche Diagnostics, Almere, The Netherlands)
were used to determine blood plasma levels of glucose, triglycerides,
and HDL-cholesterol. Glucose was measured spectrophotometrically
with an enzymatic hexokinase method. Triglyceride levels were mea-
sured with an enzymatic colorimetric method. HDL-cholesterol levels
were quantiﬁed using an enzymatic colorimetric test after complexa-
tion of the chylomicrons. Between day coefﬁcients of variation were
0.9–1.0% for glucose, 1.0% for triglycerides and 2.1–3.0% for HDL choles-
terol. In the NESDA study, blood pressure was deﬁned as the average of
Bipolar patients from the
Bipolar Stress Study
(n = 122)
Participants from NESDA
(n = 2,596)
6 (4.9%) excluded:
age > 65 yr
BD patients
(n = 241)
MDD patients
(n = 1,648)
Healthy controls
(n = 542)
Subjects included in the
present study
(n = 2,431)
281 (10.8%) excluded:
276 anxiety disorder only
5 dysthymia only
N=Number, BD= bipolar disorder, MDD= major depressive disorder, 
NESDA= the Netherlands Study of Depression and Anxiety
Fig. 1. Flow-chart diagram of the participants. N = Number, BD= bipolar disorder, MDD=major depressive disorder, NESDA= the Netherlands Study of Depression and Anxiety.
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Inc., Bannockburn, IL, USA) blood pressuremonitor readings on the right
arm, with the respondent in supine position. In the Bipolar Stress Study,
blood pressure was accordingly measured only once on the right arm
using Omron M6 IntelliSense (Omron Healthcare, Inc., Bannockburn,
IL, USA).
Covariates
Sociodemographic characteristics included age, sex, ethnicity (non-
North-European descent/North-European descent), and level of educa-
tion (basic—less than 9 years of schooling; intermediate—less than
15 years of schooling; high—more than 15 years of schooling). Smoking
status was used as a binary variable (non-smoker/smoker).
A previous study indicated that MetS abnormalities were mainly
linked to the severity of symptoms, suggesting state associations and
less clear trait associations [25]. Therefore, analyses were adjusted for
the severity of the depressive symptoms in the case of BD and MDD
patients. The severity of depressive symptoms was measured using
a shortened version (QIDS-sr16) of the Inventory of Depressive
Symptomatology (IDS-SR). IDS-SR is a self-administered questionnaire
designed to assess the severity of depressive symptoms [28,29]. It
assesses all DSM-IV criterion symptom domains for major depressive
disorder plus commonly associated symptoms (e.g. anxiety, irritability)
and symptoms relevant to melancholic and atypical features. The ques-
tionnaire consists of 30 items, each with four answering options (coded
0 through 3). The questionnaire uses a 7-day timeframe for assessing
symptom severity. The QIDS-sr16 is a shortened version of the IDS-SR
that includes only the 9 criterion symptom domains of MDD, using 16
items of the IDS-SR. Scores on the QIDS-sr16 range from 0 to 27.
Antidepressant (ATC code N06Ax), lithium (ATC code N05AN), and
antipsychotic medication (ATC code N05Ax) use within the past month
were coded according to the Anatomical Therapeutic Chemical (ATC)
Classiﬁcation System (http://www.whocc.no/). Antidepressant use was
subdivided into SSRI (ATC code N06AB), TCA (ATC code N06AA), and
other antidepressants (mainly serotonergic and noradrenergic-working
antidepressants; N06AF and N06Ax).
In the present study, the proportions of missing data for some vari-
ables were as follows: smoking status 0.9%; the severity of depressive
symptoms 3.5%, SSRI 0.2%; TCA 0.2%; and other antidepressants 0.1%.
Statistical analyses
Non-normally distributed variables (i.e., number ofMetS components,
HDL-cholesterol, triglyceride, glucose) were naturally log-transformed.Sociodemographic and clinical characteristics of BD, MDD, or non-
psychiatric control groups were compared usingχ2 tests for categorical
variables and analysis of variance (ANOVA) for continuous variables.
For the presence of MetS, two comparisons were made using multivar-
iate logistic regression analyses: ﬁrst the BD group was compared with
the MDD group, and second the BD group was compared with the non-
psychiatric control group, adjusted for age, sex, ethnicity, level of educa-
tion, and smoking status in Model 1. In Model 2, the severity of the
depressive symptoms was added as a covariate to those of Model 1.
For the total number of MetS components and for each MetS compo-
nent we used ANOVA and analysis of covariance (ANCOVA). Two
post-hoc (LSD) comparisons were made: ﬁrst the BD group was com-
pared with the MDD group, and second the BD group was compared
with the non-psychiatric control group. In ANCOVA, adjustments were
done for age, sex, ethnicity, level of education, and smoking status
(in Model 1), and in Model 2, the severity of depressive symptoms
was added to those of Model 1. Next, focusing on the 241 BD patients,
we explored which variables contributed to the presence of MetS, to
the total number of MetS components, or to the individual components
ofMetS usingmultivariate regression analyses. These variables included
age, sex, ethnicity, level of education, smoking status, severity of
depressive symptoms, and use of lithium, antipsychotic medication,
SSRIs, TCAs, and other antidepressants yielding standardized beta-
coefﬁcients or odds ratios (ORs) with their 95% conﬁdence intervals
(CI), for continuous and dichotomous (i.e. presence of MetS) variables,
respectively. All analyses were performed using the statistical software
IBM SPSS 20.0 for Windows (IBM company, Chicago, Illinois, USA).
Statistical signiﬁcance was inferred at p b 0.05.
Results
Characteristics of the sample
The sociodemographic status, smoking status, and clinical characteristics of the
participants are shown in Table 1 according to their DSM-IV diagnosis and in Table 2
according to the severity of depressive symptoms. The mean age of the total sample was
44.3 years (SD 13.0), where 66.1% of the sample was female and 95.6% of the sample
was of North-European descent.
Differences in MetS characteristics according to the presence of BD
Table 3 compares the MetS characteristics of BD patients with those of MDD patients,
and non-psychiatric controls. Patients with BD had a signiﬁcantly higher prevalence of
MetS compared to patients with MDD and non-psychiatric controls (28.4% vs. 20.2% and
16.5%, respectively, p b 0.001). These differences remained statistically signiﬁcant after
multivariable adjustment (OR 1.52, 95% CI: 1.09–2.12, p = 0.02 when compared to
MDD; OR 1.79, 95% CI: 1.20–2.67, p= 0.005 when compared to non-psychiatric control
Table 1
Characteristics of the total sample and subsamples according to the type of DSM-IV diagnoses
Total sample BD MDD Non-psychiatric controls p-value
No. of participants 2431 (100%) 241 (9.9%) 1648 (67.8%) 542 (22.3%)
Age 0.01
Mean (±SD) 44.33 (±12.96) 46.45 (±11.60) 44.34 (±12.54) 43.37 (±14.61)
Range 19–68 20–67 19–68 20–67
Sex b0.001
Males 823 (33.9%) 98 (40.7%) 512 (31.1%) 213 (39.3%)
Females 1608 (66.1%) 143 (59.3%) 1136 (68.9%) 329 (60.7%)
Ethnicity 0.06
Non-North-European ancestry 106 (4.4%) 6 (2.5%) 83 (5.0%) 17 (3.1%)
North-European ancestry 2325 (95.6%) 235 (97.5%) 1565 (95.0%) 525 (96.9%)
Level of education b0.001
Basic 158 (6.5%) 37 (15.4%) 103 (6.2%) 18 (3.3%)
Intermediate 1289 (53.0%) 106 (44.2%) 932 (56.6%) 251 (46.3%)
High 983 (40.4%) 97 (40.4%) 613 (37.2%) 273 (50.4%)
Smoking status b0.001
Non-smoker 1637 (67.3%) 139 (59.4%) 1062 (65.0%) 436 (80.6%)
Smoker 773 (31.8%) 95 (40.6%) 573 (35.0%) 105 (19.4%)
Psychotropic medication use
SSRI 347 (14.3%) 43 (18.0%) 301 (18.3%) 3 (0.6%) b0.001
TCA 71 (2.9%) 14 (5.8%) 56 (3.4%) 1 (0.2%) b0.001
Other AD 155 (6.4%) 37 (15.4%) 116 (7.0%) 2 (0.4%) b0.001
Antipsychotic medication 89 (3.7%) 61 (25.4%) 28 (1.7%) 0 (0.0%) b0.001
Lithium 102 (4.2%) 97 (40.2%) 5 (0.3%) 0 (0.0%) b0.001
Antiepileptic medication 68 (2.8%) 35 (14.5%) 29 (1.8%) 4 (0.7%) b0.001
The severity of depressive symptoms (QIDS) b0.001
Mean (±SD) 6.30 (±4.78) 8.54 (±5.49) 7.19 (±4.78) 2.68 (±2.39)
Range 0–24 0–24 0–23 0–14
Abbreviations: BD, bipolar disorder; MDD, major depressive disorder; SD, standard deviation.
NOTE: the signiﬁcant differences in the psychotropic medication use between BD and MDD were as follows: SSRI and TCA: p N 0.05; Other AD, antipsychotic medication, lithium,
antiepileptic medication: p b 0.001.
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number of MetS components between BD and MDD or non-psychiatric control subjects.
Regarding individual MetS components, statistically signiﬁcant differences between
subjects with BD and non-psychiatric controls were found in multivariable models for
waist circumference (higher mean levels in BD than non-psychiatric controls; 91.0 cmTable 2
Characteristics of the participants according to the severity od depressive symptoms
BD
Symptomatic
patients
Non-symptomatic
patients
No. of participants 144 86
Age
Mean (±SD) 46.45 (±11.50) 46.72 (±11.87)
Range 20–67 23–67
Gender
Males 51 (35.4%) 42 (48.8%)
Females 93 (64.6%) 44 (51.2%)
Ethnicity
Non-North-European ancestry 4 (2.8%) 1 (1.2%)
North-European ancestry 140 (97.2%) 85 (98.8%)
Level of education
Basic 21 (14.6%) 15 (17.6%)
Intermediate 72 (50.0%) 30 (35.3%)
High 51 (35.4%) 40 (47.1%)
Smoking status
Non-smoker 82 (57.3%) 54 (65.1%)
Smoker 61 (42.7%) 29 (34.9%)
Psychotropic medication use
SSRI 28 (19.7%) 14 (16.3%)
TCA 7 (4.9%) 7 (8.1%)
Other AD 24 (16.9%) 10 (11.6%)
Antipsychotic medication users 32 (22.4%) 24 (27.9%)
Lithium users 42 (29.2%) 49 (57.0%)
Antiepileptic medication users 15 (10.4%) 18 (20.9%)
The severity of depressive symptoms (QIDS)
Mean (±SD) 11.83 (±4.21) 3.04 (±1.52)
Range 6–24 0–5
Abbreviations: BD, bipolar disorder; MDD, major depressive disorder; SD, standard deviation.
Note: patients—with a QIDS-sr16 score ≥ 6 (mild to severe symptoms); Non-symptomatic patvs. 88.8 cm, respectively; p = 0.03) and systolic blood pressure (lower mean levels in
BD than non-psychiatric controls; 132.7 mmHg vs. 135.6 mmHg, respectively; p= 0.03).
Next we conducted a stratiﬁed analysis according to the severity of depressive symp-
toms. Therewere 779 patients (35.7% of patientswith BDand42.1% of patientswithMDD)
with a QIDS-sr16 score less than 5 (i.e., no symptoms) and 1037 patients (59.8% of patientsMDD
Differences btw.
groups
Symptomatic
patients
Non-symptomatic
patients
Differences btw.
groups
893 693
p = 0.87 p = 0.24
44.89 (±12.48) 44.10 (±12.67)
19–66 20–68
p = 0.045 p = 0.13
288 (32.3%) 199 (28.7%)
605 (67.7%) 494 (71.3%)
p = 0.42 52 (5.8%) 22 (3.2%) p = 0.01
841 (94.2%) 671 (96.8%)
p = 0.09 p b 0.001
64 (7.2%) 30 (4.3%)
547 (61.3%) 348 (50.2%)
282 (31.6%) 315 (45.5%)
p = 0.25 p = 0.21
567 (63.9%) 462 (66.9%)
321 (36.1%) 229 (33.1%)
p = 0.52 182 (20.5%) 101 (14.6%) p = 0.002
p = 0.33 40 (4.5%) 14 (2.0%) p = 0.01
p = 0.28 66 (7.4%) 39 (5.6%) p = 0.15
p = 0.35 22 (2.5%) 5 (0.7%) p = 0.01
p b 0.001 4 (0.4%) 1 (0.1%) p = 0.39
p = 0.03 21 (2.4%) 8 (1.2%) p = 0.03
p b 0.001 p b 0.001
10.49 (±3.74) 3.15 (±1.32)
6–23 1–5
ients—with a QIDS-sr16 less than 5 (no symptoms).
Table 3
Prevalence of the metabolic syndrome, number of metabolic syndrome components and mean metabolic syndrome components according DSM-IV diagnosis
BD MDD p-value for
BD vs. MDD
Controls p-value for
BD vs. Controls
No. of participants 229 1464 498
Metabolic syndrome 65 (28.4%) 296 (20.2%) 0.004 82 (16.5%) b0.001
No. of MetS components
Crude 1.65 (0.09) 1.39 (0.03) 0.004 1.30 (0.05) 0.001
Adjusteda 1.53 (0.08) 1.39 (0.03) 0.09 1.37 (0.05) 0.08
Adjustedb 1.48 (0.08) 1.38 (0.03) 0.24
Waist circumference
Crude 92.2 (0.03) 90.1 (0.01) 0.03 88.8 (0.02) 0.002
Adjusteda 91.0 (0.84) 90.3 (0.32) 0.43 88.8 (0.57) 0.03
Adjustedb 90.4 (0.86) 90.2 (0.33) 0.78
Triglyceride level
Crude 1.46 (0.03) 1.37 (0.01) 0.22 1.30 (0.02) 0.06
Adjusteda 1.38 (0.07) 1.37 (0.03) 0.91 1.33 (0.05) 0.59
Adjustedb 1.36 (0.07) 1.37 (0.03) 0.84
HDL-cholesterol
Crude 1.47 (0.03) 1.55 (0.01) 0.02 1.54 (0.02) 0.04
Adjusteda 1.50 (0.03) 1.54 (0.01) 0.12 1.55 (0.02) 0.08
Adjustedb 1.50 (0.03) 1.54 (0.01) 0.12
Systolic blood pressure
Crude 134.9 (1.23) 133.0 (0.48) 0.16 135.4 (0.89) 0.08
Adjusteda 132.7 (1.09) 133.3 (0.42) 0.59 135.6 (0.74) 0.03
Adjustedb 132.6 (1.12) 133.3 (0.43) 0.55
Diastolic blood pressure
Crude 81.1 (0.74) 79.8 (0.28) 0.11 79.3 (0.52) 0.04
Adjusteda 80.0 (0.67) 79.9 (0.26) 0.84 79.5 (0.45) 0.49
Adjustedb 79.8 (0.67) 79.9 (0.26) 0.95
Glucose level
Crude 5.31 (0.11) 5.36 (0.03) 0.02 5.31 (0.05) 0.009
Adjusteda 5.46 (0.07) 5.36 (0.03) 0.17 5.34 (0.05) 0.15
Adjustedb 5.46 (0.07) 5.36 (0.05) 0.23
Data are mean values (standard errors) assessed by one-way ANOVA and univariate ANCOVA.
BD, bipolar disorder; MDD, major depressive disorder; MetS, metabolic syndrome.
Note: the severity of depressive symptoms was added to the Models only in groups with BD and MDD.
Bold values indicate signiﬁcance at b 0.05.
a Adjusted for age, sex, ethnicity, level of education, and smoking status.
b Adjusted for age, sex, ethnicity, level of education, smoking status and the severity of depressive symptoms.
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symptoms). In logistic regression analyses, we found that the difference between the
groups with BD and MDD was more pronounced in symptomatic (depressed) than non-
symptomatic patients, with adjusted odds ratios of 1.71 (95% CI: 1.12–2.61; p = 0.01)
vs. 1.03 (95% CI: 0.56–1.90; p= 0.92), respectively. This indicates that BD patients were
at a higher risk of developingMetS compared toMDDpatientswhen theywere symptom-
atic but not when they were non-symptomatic.
Determinants of the MetS (components) in patients with BD
Table 4 shows the potential independent correlates of MetS (components) in the 241
BD patients. Advanced age and male sex were the most important risk factors for MetS
(components) in BD. Thesewere signiﬁcant predictors of a higher number ofMetS compo-
nents, larger waist circumference, higher triglyceride level, higher systolic and diastolic
blood pressure, higher glucose level and lower HDL-cholesterol in BD patients (Table 4).
Sensitivity analyses have shown that the type of BD (BD type I and BD type II) was not a
signiﬁcant predictor of MetS and its components. Lastly, only age (per 10 years, OR 1.5,
95% CI: 1.18–1.81, p = 0.002) and basic or intermediate education (OR 2.69, 95% CI:
1.31–5.52, p= 0.01) were signiﬁcantly associated with higher odds for developing MetS
in BD patients (Table 4).
Discussion
This study supports evidence that individuals with BD have a higher
prevalence of MetS than those with MDD and non-psychiatric controls.
This could partly be ascribed to a higher prevalence of abdominal obesi-
ty in individuals with BD compared to individuals with no history ofpsychiatric disorders. Advanced age andmale sexwere themost impor-
tant risk factors for MetS in BD, but psychotropic use did not contribute
to the presence of MetS.
Our ﬁnding that BD patients have a higher prevalence of MetS than
MDD patients and non-psychiatric controls is consistent with previous
ﬁndings in other BD populations. The odds ratio of 1.8 was similar to
the prevalence proportion ratios of approximately 1.6 when compared
to the general population (as summarized in a previous review by
Murray et al. [8]). The prevalence rate of MetS in our BD group was
28.4%, which was comparable to the mean prevalence of 29.9% using
the deﬁnition of ATP-III from 18 studies, as summarized in a meta-
analysis [6]. TheMetS prevalence of 16.5% in controlswas also compara-
ble to the estimated 14% prevalence of MetS in two Dutch population-
based studies [30]. Our stratiﬁed analyses suggested that the differences
weremediated in part by the severity of depressive symptoms, which is
in line with the analysis of Van Reedt Dortland et al. [25]. That study
concluded that the prevalence of MetS was not higher in subjects with
MDD when compared to controls, but subjects with more severe
depressive symptoms had higher odds of the presence of MetS. Thus
current disease severity may be a stronger risk factor than diagnostic
DSM-IV categories with respect to the risk of MetS.
Possible aetiological explanations for the higher risk of MetS in BD
may be disturbances in the hypothalamic–pituitary–adrenal (HPA)
axis, low-grade chronic inﬂammation, the sympathetic nervous system
Table 4
Potential determinants of the metabolic syndrome (components) in 241 patients with Bipolar Disorder
MetS (yes/no)
Odds ratio (95% CI)
No. of MetS components
β-coefﬁcient (p-value)
Waist circumference
β-coefﬁcient (p-value)
Triglyceride level
β-coefﬁcient (p-value)
Age (per 10 years) 1.49 (1.18–1.81)⁎⁎ 0.30 (b0.001) 0.19 (b0.001) 0.17 (0.01)
Female sex 0.54 (0.28–1.05) −0.26 (b0.001) −0.44 (b0.001) −0.16 (0.03)
Non-North-European ancestry 0.22 (0.02–3.25) 0.10 (0.11) 0.05 (0.44) −0.01 (0.83)
Basic or intermediate education 2.69 (1.31–5.52)⁎⁎ 0.17 (0.01) 0.07 (0.24) 0.09 (0.17)
Smoker 1.35 (0.70–2.63) 0.05 (0.46) −0.03 (0.60) 0.13 (0.05)
Lithium use 0.99 (0.48–2.06) 0.08 (0.24) −0.05 (0.44) 0.03 (0.71)
Antipsychotic use 0.93 (0.42–2.08) 0.08 (0.21) 0.04 (0.52) 0.01 (0.94)
SSRI use 1.36 (0.61–3.03) 0.03 (0.63) −0.01 (0.84) 0.07 (0.30)
TCA use 0.82 (0.19–3.45) 0.02 (0.74) −0.03 (0.69) 0.13 (0.07)
Other AD use 1.24 (0.52–2.95) −0.03 (0.68) −0.02 (0.72) 0.02 (0.74)
The severity of depressive symptoms 1.02 (0.96–1.09) 0.03 (0.63) −0.02 (0.73) 0.16 (0.02)
HDL-cholesterol
β-coefﬁcient (p-value)
Systolic blood pressure
β-coefﬁcient (p-value)
Diastolic blood pressure
β-coefﬁcient (p-value)
Glucose level
β-coefﬁcient (p-value)
Age (per 10 years) 0.08 (0.22) 0.36 (b0.001) 0.30 (b0.001) 0.33 (b0.001)
Female sex 0.36 (b0.001) −0.36 (b0.001) −0.26 (b0.001) −0.17 (0.01)
Non-North-European ancestry −0.07 (0.32) −0.02 (0.78) −0.06 (0.35) 0.15 (0.03)
Basic or intermediate education −0.09 (0.18) 0.14 (0.02) 0.05 (0.42) 0.02 (0.82)
Smoker −0.08 (0.26) −0.02 (0.68) 0.01 (0.92) 0.13 (0.05)
Lithium use −0.02 (0.75) 0.07 (0.29) −0.09 (0.21) −0.02 (0.77)
Antipsychotic use −0.03 (0.64) −0.01 (0.84) 0.08 (0.21) 0.07 (0.33)
SSRI use 0.02 (0.80) 0.05 (0.39) 0.01 (0.97) −0.04 (0.56)
TCA use 0.03 (0.65) −0.01 (0.95) 0.01 (0.88) −0.05 (0.49)
Other AD use −0.07 (0.29) −0.08 (0.16) 0.15 (0.02) −0.07 (0.29)
The severity of depressive symptoms −0.01 (0.84) 0.01 (0.88) 0.04 (0.58) 0.01 (0.85)
Note: There were missing for some variables as follows: the number of MetS components 5.0%; waist circumference 4.1%; triglyceride level 6.6%; HDL-cholesterol 6.6%; systolic and
diastolic blood pressure 3.0%; glucose level 6.6%; smoking status 3.0%; the severity of depressive symptoms 4.5%; SSRI 0.8%; TCA 0.4%; and other antidepressants 0.4%.
Bold values indicate signiﬁcance at p b 0.05.
⁎⁎ p b 0.01
396 B. Silarova et al. / Journal of Psychosomatic Research 78 (2015) 391–398[31], and adverse lifestyle factors. First, to bemore speciﬁc, HPA axis dys-
function is a well-recognized characteristic in patients with BD [32],
which might explain the association between BD and MetS. Although
difﬁcult to determine with current methods of measurement using
serum or saliva, systemic cortisol actionmay be elevated due to disturbed
negative feedback at the hypothalamic or pituitary level in both BD and
MDD patients. One of the most typical cortisol effects is redistribution
of adipose tissue with fat accumulation in the abdominal region. In the
long run this could lead to abdominal obesity. Genetically-determined
disturbances of glucocorticoid sensitivity may increase the risk of both
BD and MDD [33]. Interestingly, parallel to hypercortisolism due to
endogenous or exogenous Cushing's syndrome, increased sensitivity to
glucocorticoids has also been associated with features of the MetS [34].
Second, the higher risk of cardiac disease, diabetes, and metabolic
abnormalities in BD subjects may be explained by an increased low-
grade inﬂammatory state [30]. High levels of proinﬂammatory cyto-
kines and acute-phase reactants were associated with MetS as well as
with BD and MDD [31,35]. Recent studies have found that BD is associ-
ated with increased expression of pro-inﬂammatory markers including
acute-phase proteins, like C-reactive protein, and cytokines, like
interleukin-6 and interferon-γ, which may contribute to the presence
of the abovementioned disorders [31]. Abdominal fat tissue is known
to be metabolically highly active, with consequences for inﬂammatory
status [36].
Third, the metabolic abnormalities in BD may be explained by a
stimulated sympathetic nervous system, which has been found in indi-
viduals with BD [31]. In response to dietary intake, insulin-mediated
glucose uptake in the central nervous system regulates sympathetic
nervous system activity. Insulin-mediated sympathetic stimulation
may subsequently contribute to hypertension [37].
Fourth, adverse lifestyle factors, such as smoking, alcohol intake,
poor-quality diets (energy-dense diets that are nutrient-poor), and
lack of exercise, are highly prevalent in BD patients and may explain
the higher prevalence of metabolic abnormalities among those with
BD [5,31]. Available data regarding the association between smokingand MetS are inconsistent, but a recent meta-analysis by Sun, Liu and
Ning [38] based on data from prospective studies concluded that active
smoking is associatedwith the development of MetS. The risk of alcohol
abuse is higher in BD patients [39], which increases the risk of pancrea-
titis and consequently diabetes [9]. Additionally, physical inactivity and
poor dietary habits have been reported in BD and are associated with
weight gain and obesity [31].
We found that abdominal obesity was the MetS component most
strongly associated with BD diagnosis, while systolic blood pressure
was lower when compared to controls. The majority of previous studies
among patients with BD also indicate that abdominal obesity is the key
metabolic abnormality present among 18%–61% BD patients [40,41].
Generally, NCEP ATPIII emphasized the importance of abdominal obesity
as the driving force of MetS [5,23], which may subsequently increase the
risk for cardiovascular disease and type 2 diabetes in peoplewith BD [31].
Lastly, in the present study, psychotropic use was not a signiﬁcant
predictor of MetS or its individual components in BD. Previous studies
have reported that the use of lithium, valproic acid, and atypical anti-
psychotics (e.g. olanzapine, clozapine) contributed to obesity and
MetS in the BD group, mainly due to the effects on appetite and glucose
and lipid metabolism [5,42]. Similarly, a recent meta-analysis [6] indi-
cated that patients taking antipsychotics might be at greater risk for
MetS compared to those who were not using such medication. On the
contrary, other studies [16,43], similar to our study, have not found
such an association. This might be due to the naturalistic design:
obese patients or those with other cardiometabolic risk factors may be
less likely to be prescribed psychotropic medication that exacerbates
the general metabolic condition, resulting in some confounding by
treatment indication. However, it is also possible that glucose and
lipid metabolism disturbances were already present in many BD
patients before starting to use psychotropic medications [5], and recent
evidence showed that BD was often associated with weight gain, inde-
pendent of psychotropic treatment [44]. As most of our bipolar patients
were not drug-naive, future studies should also include drug-naive
bipolar patients.
397B. Silarova et al. / Journal of Psychosomatic Research 78 (2015) 391–398Strengths and limitations
Our study has several strengths. First, this studywas based on a large
multi-center sample, with a signiﬁcant group of patients with BD (n=
241). Second, the sample included in this study covered awide-range of
demographic characteristics among adult patients with BD and MDD
(e.g., both genders and broad ranges of age and severity of depressive
symptoms). Third, this study used both individuals with MDD and no
history of psychiatric disorders as groups of comparison whereas most
of previous studies focusing on the prevalence ofMetS in BDused either
non-psychiatric controls or subjects with schizophrenia.
There are also certain limitations of this study that should be consid-
ered. First, our cross-sectional design did not allow us to make causal in-
ferences onwhether psychopathology precedesmetabolic abnormalities
or vice versa. Next, wewere unable to control for lifestyle indicators such
as dietary intake, alcohol use, and physical activity. Third, the smoking
status in the Bipolar Stress Study was measured only at the baseline
and thus provided only a proxy indicator of smoking habits at the two-
year mark. Fourth, the methods of assessment of MetS components
differed somewhat between BD patients in NESDA and the Bipolar Stress
Study. However, mean values of MetS components were similar for
NESDA and the Bipolar Stress Study, except for HDL-cholesterol levels
(p = 0.03). Fifth, manic symptoms were not assessed. Sixth, the
prescription rates of psychotropic medication in this study reﬂect that
we also included non-symptomatic participants with lifetime diagnoses
of bipolar and depressive disorders. Moreover, some participants might
have substantial beneﬁt of other (psycho) therapeutic interventions to
remain stable and this may inﬂuence the need of medication. Next, the
concept of MetS has been criticized by the American Diabetes Associa-
tion [45], which led us to analyze a dichotomous MetS indicator in addi-
tion to the individual components and the number ofMetS components.
This allowed us to conﬁrm that some components (abdominal obesity)
were more associated with BD than other components. Nevertheless,
the WHO report [46], the American Heart Association, and the National
Heart Lung and Blood Institute concluded that MetS is a concept with
clinical relevance [6]. Eight, the original ATP III criteria [24] were used
instead of the adjusted ATP III criteria [47,48], as information regarding
nicotinic acid and derivatives of lovastatin andnicotinic acidwasmissing
in the Bipolar Stress study.
Implications
We found that subjects with BD compared to those with MDD or no
history of a psychiatric disorder had a higher prevalence of MetS, with
the strongest contribution of abdominal obesity speciﬁcally in patients
with symptomatic depression. The relatively high prevalence of MetS
in the BD population therefore requires attention from both clinicians
and researchers. Clinically, it might be relevant to apply individualized
treatment for BD patients that also includes assessment of metabolic
risk factors, psychoeducation, weight loss intervention [49], and
improvement of health-related behaviors [5,50]. Additional research is
needed to further examine the exact pathogenesis of MetS in BD and
(severe) MDD patients. For instance, in addition to adverse lifestyle
factors and medication, other potential commonly-shared aetiological
pathways leading to both psychiatric disease andMetS (e.g. hyperactivity
of theHPAaxis and low-grade inﬂammation) should be further explored.
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